Frontline Pharma: Sarah O’Keeffe - Summary - MDSpire
Feature

Frontline Pharma: Sarah O’Keeffe

Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients

  • By

  • James Strachan

  • May 8, 2026

  • 16 min

Share

Eli Lilly's newly approved obesity medication, orforglipron (Foundayo), represents significant progress in medication delivery for patients. Developed by Sarah O’Keeffe and her team, the synthesis process is notably efficient, enhancing sustainability and reducing waste. O’Keeffe discusses her transition from hands-on science to leadership, the increasing complexity of modern therapies, and the critical integration of various scientific disciplines in pharmaceutical innovation. Her upcoming keynote at HPLC 2026 will delve into the transformative role of advanced data science and automation in drug development.

Original Source(s)

Frontline Pharma: Sarah O’Keeffe

  • by James Strachan

  • May 8, 2026

Related Content

Ancient DNA Tracks 10,000 Years of Selection

Large dataset shows widespread genetic changes shaping modern traits and disease risk

  • May 12, 2026

  • 3 min
Remote Diet Support Studied in Diabetes

WhatsApp-based low-carbohydrate nutrition education was linked to short-term glycemic, weight, and medication-use improvements in a small primary care trial

Wearables May Boost T2D Mobility

Outpatient intervention combined physiotherapist counseling with wrist-worn activity monitoring.